✉ Email this page to a colleague
« Back to Dashboard
Lucerastat is an investigational drug.
There have been 7 clinical trials for Lucerastat. The most recent clinical trial was a Phase 3 trial, which was initiated on December 18th 2018.
The most common disease conditions in clinical trials are Fabry Disease and [disabled in preview]. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and [disabled in preview].
There are fifty-eight US patents protecting this investigational drug and three hundred and sixty-six international patents.
Recent Clinical Trials for Lucerastat
|A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function||Idorsia Pharmaceuticals Ltd.||Phase 1|
|A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease||Idorsia Pharmaceuticals Ltd.||Phase 3|
|Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease||Idorsia Pharmaceuticals Ltd.||Phase 3|
Top disease conditions for Lucerastat
Top clinical trial sponsors for Lucerastat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lucerastat||See Plans and Pricing||Cell lines for virus production and methods of use||University of Georgia Research Foundation, Inc. (Athens, GA) The United States of America, as represented by the Secretary, Dept. of Health and Human Services (Washington, DC) Thermo Fisher Scientific, Inc. (Waltham, MA)||See Plans and Pricing|
|Lucerastat||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Lucerastat||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Lucerastat||See Plans and Pricing||Compartmented pharmaceutical dosage forms||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Lucerastat||See Plans and Pricing||Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad||NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (Chiba-Shi, JP)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Lucerastat||Australia||AU2014215025||2033-02-05||See Plans and Pricing|
|Lucerastat||Canada||CA2899928||2033-02-05||See Plans and Pricing|
|Lucerastat||China||CN105121645||2033-02-05||See Plans and Pricing|
|Lucerastat||China||CN108588027||2033-02-05||See Plans and Pricing|
|Lucerastat||European Patent Office||EP2954055||2033-02-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|